Exchange Traded Concepts LLC Has $169,000 Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Exchange Traded Concepts LLC lowered its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 11.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 12,872 shares of the company’s stock after selling 1,617 shares during the period. Exchange Traded Concepts LLC’s holdings in Y-mAbs Therapeutics were worth $169,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its position in shares of Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares during the period. SG Americas Securities LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $178,000. XTX Topco Ltd acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $297,000. Caxton Associates LP acquired a new position in shares of Y-mAbs Therapeutics in the 1st quarter worth approximately $306,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Y-mAbs Therapeutics by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,000 shares of company stock worth $1,338,100. Insiders own 21.50% of the company’s stock.

Y-mAbs Therapeutics Trading Up 0.8 %

YMAB opened at $14.56 on Tuesday. The company’s fifty day moving average price is $13.69 and its two-hundred day moving average price is $13.13. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.69 and a 1-year high of $20.90. The company has a market cap of $638.94 million, a price-to-earnings ratio of -29.71 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the previous year, the company posted ($0.14) EPS. As a group, equities analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

YMAB has been the topic of a number of research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets dropped their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.